



Electronic Health Record (EHR)

Instructions to Create an Order Set for Atopic Dermatitis (AD) With NEMLUVIO® in the Epic® EHR System

IMPORTANT SAFETY INFORMATION

INDICATION: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

Please see Important Safety Information on page 7 and accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.

Background, Instructions, and Limitations

Indication

NEMLUVIO is indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.¹

Limitations of Use

These instructions were created specifically to update an order set in the Epic EHR system and will not work in other EHR systems. These instructions are designed to be used for NEMLUVIO for the treatment of AD and should not be used for other conditions, treatments, or therapeutic areas.

The processes outlined in this piece are variable and not all steps will apply to every health system. Any steps or settings that are not part of a health system's standard process should be excluded or modified accordingly. Any questions should be directed to the appropriate service provider. The practice is solely responsible for implementing, testing, monitoring, and ongoing operation of any EHR tools.

A health system may choose to optimize existing EHR order sets or to create a new order set for NEMLUVIO. Order sets consolidate notes, referrals, imaging studies, lab orders and bundles, medications, patient education, coding and billing information, and other orderable items used to manage a condition or problem. Order sets can improve the user experience and help reduce practice variation. These instructions detail specifically how to add the initiation and maintenance dosing of NEMLUVIO to an order set.

AD, atopic dermatitis; EHR, electronic health record.

Please see Important Safety Information on page 7 and accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.

Recommended Dosage of NEMLUVIO for AD¹:



- Concomitant topical therapies:

- Use NEMLUVIO with topical corticosteroids and/or topical calcineurin inhibitors. When the disease has sufficiently improved, discontinue use of topical therapies¹

Complete all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with NEMLUVIO [see *Warnings and Precautions* (5.2)].¹

Review the NEMLUVIO Prescribing Information for additional information, including important administration instructions, preparation for use of NEMLUVIO, missed dose information, and additional information.

Mechanism of Action

- NEMLUVIO is a humanized monoclonal antibody of the IgG2 subclass that inhibits IL-31 signaling by binding selectively to IL-31RA¹
- IL-31 is a naturally occurring cytokine that is involved in pruritis, inflammation, epidermal dysregulation, and fibrosis¹
- NEMLUVIO inhibited IL-31-induced responses including the release of proinflammatory cytokines and chemokines¹

AD, atopic dermatitis; IgG, immunoglobulin G; IL-31RA, interleukin-31 receptor alpha; Q8W, every 8 weeks.

Please see Important Safety Information on page 7 and accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.

Epic Instructions


Updating existing SmartSets requires minimal time but must be implemented at the system level. First, identify the SmartGroups with the moderate-to-severe AD medications listed. Once a SmartGroup has been optimized, it may be used in SmartSets.

Step 1 - Update the SmartGroup:

- 1 Open the management console **Tools > Management Console** (use of the management console typically requires appropriate user rights and privileges)
- 2 Select **SmartGroups** from the **Decision Support** menu to launch a new window
- 3 **Select** the desired SmartGroup (OSQ record) to be modified (one or more moderate-to-severe AD medication SmartGroups may be available). If there are no existing SmartGroup records, consider creating a new SmartGroup. If desired, other SmartGroups may be updated
 - For the General – Provider and Nursing Notes SmartGroup (naming conventions and selections of the appropriate SmartGroup may vary, review which SmartGroup may be most relevant based on system naming conventions and guidelines), consider adding:

The hyperlink to the current NEMLUVIO PI (which includes the NEMLUVIO recommended vaccinations prior to treatment initiation, dosage and administration, warnings and precautions, and adverse reactions):

https://www.galderma.com/sites/default/files/2024-08/Nemluvio_ospippi0812.pdf




The hyperlink and QR code accessing the NEMLUVIO enrollment form. Note: the patient enrollment form has 2 prescriptions on the bottom of the form (for quick start and regular prescription):

<https://www.nemluviohcp.com/pdf/enrollment-form.pdf>




The hyperlink to the NEMLUVIO patient savings card for Commercial patients:

<https://www.GaldermaHCP.Portal.com>



NEMLUVIO has a limited distribution network and is available at:

<https://www.nemluviohcp.com/pdf/specialty-pharmacy-facts.pdf>



Alternatively, this information can be added to the NEMLUVIO Order Composer settings (see Step 8 on the next page)

- 4 Click the **Create** tab
- 5 Update the **Name, ID, Contact Date,** and **Record Type** of the SmartGroup if needed. Click Accept once done

Instructions continued on the next page.

AD, atopic dermatitis; PI, Prescribing Information.

Please see Important Safety Information on page 7 and accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.

Epic Instructions (cont'd)

- 6 Click **Configuration** from the menu
- 7 Click **Add Item** and select the **Item Type** (example: Medications)
- 8 Add the NEMLUVIO initiation and maintenance dosing formulations:

For the NEMLUVIO maintenance dosing, complete the medication details below¹:*

Consider adjusting the Order Composer as per the health system's governing SmartGroup convention

- The recommended initiation dosage of NEMLUVIO in patients aged 12 years and older is
 - An initial dose of 60 mg (two 30 mg injections)
- **Concomitant topical therapies:**
 - Use NEMLUVIO with topical corticosteroids and/or topical calcineurin inhibitors. When the disease has sufficiently improved, discontinue use of topical therapies¹

For the NEMLUVIO maintenance dosing, complete the medication details below¹:*

- The recommended maintenance dosage of NEMLUVIO in patients aged 12 years and older is
 - A maintenance dosing of 30 mg given every 4 weeks (Q4W)
 - After 16 weeks of treatment, for patients who achieve clear or almost clear skin, a dosage of 30 mg Q4W or every 8 weeks (Q8W) is recommended
- **Concomitant topical therapies:**
 - Use NEMLUVIO with topical corticosteroids and/or topical calcineurin inhibitors. When the disease has sufficiently improved, discontinue use of topical therapies¹

- 9 Select **General Info** and set the record name, display name, and other information as desired
- 10 Release after satisfactory testing has been completed

Instructions continued on the next page.

*Maintenance dosing starts 4 weeks after initial dose.¹

Please see Important Safety Information on page 7 and accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.

Epic Instructions (cont'd)

Step 2 - Update All Applicable SmartSets:

- 1 Identify all SmartSets that would benefit from the optimized SmartGroup using search terms such as “moderate-to-severe atopic dermatitis” or “atopic dermatitis”
- 2 Update the desired SmartSets with the optimized SmartGroup record created in Step 1
- 3 Release after satisfactory testing has been completed

Notes

The customers (i.e., physician, medical group, integrated delivery network) shall be solely responsible for implementation, testing, and monitoring of the instructions to ensure proper orientation in each customer's EHR system.

Capabilities, functionality, and set up (customization) for each EHR system may vary. Galderma shall not be responsible for revising the implementation instructions it provides to any customer if the customer modifies or changes its software, or the configuration of its EHR system, after such time as the implementation instructions have been initially provided by Galderma.

While Galderma tests its implementation instructions on multiple EHR systems, the instructions are not guaranteed to work for all available EHR systems and Galderma shall have no liability thereto.

While EHRs may assist providers in identifying appropriate patients for consideration of assessment, treatment, and referral, the decision and action should ultimately be decided by a provider in consultation with the patient after a review of the patient's records to determine eligibility, and Galderma shall have no liability thereto.

The instructions have not been designed to and are not tools and/or solutions for meeting Advancing Care Information and/or any other quality/accreditation requirement.

All products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Galderma and/or its affiliates.

EHR, electronic health record.

Please see Important Safety Information on page 7 and accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.

Important Safety Information

INDICATION: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:

Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:

Most common adverse reactions (incidence $\geq 1\%$) are headache (including migraine), arthralgia, urticaria, and myalgia.

USE IN SPECIFIC POPULATIONS:

Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug-associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of NEMLUVIO has not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis.

Please see accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.

Reference: 1. NEMLUVIO. Prescribing Information. Galderma Laboratories, L.P.

© 2024 Galderma Laboratories, L.P. All rights reserved. All trademarks are the property of their respective owners. US-NAD-2400038 (12/24)